双成药业(002693) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥43,235,465.80, a decrease of 39.15% compared to the same period last year[2]. - The net profit attributable to shareholders was a loss of ¥10,410,823.84, an increase in loss of 476.31% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥13,268,205.27, an increase in loss of 275.23% year-on-year[2]. - The basic earnings per share were -¥0.0250, a decrease of 468.18% compared to the same period last year[2]. - The net profit for the third quarter was a loss of ¥17,435,104.70, compared to a loss of ¥15,445,094.69 in the previous year, indicating a worsening of approximately 12.9%[24]. - Total revenue for the third quarter of 2023 was CNY 182,248,825.90, a decrease of 7.99% compared to CNY 197,863,219.68 in the same period last year[23]. - The company's total revenue from sales of goods and services was ¥203,187,324.64, down from ¥217,137,396.25, a decline of about 6.4% year-over-year[25]. - Total operating costs for the third quarter of 2023 were CNY 213,053,392.18, down from CNY 233,827,083.27 year-over-year, indicating a reduction of 8.93%[23]. - Total comprehensive income for the period was a loss of ¥17,433,378.00, compared to a loss of ¥15,453,473.12 in the same quarter last year[24]. Assets and Liabilities - The total assets at the end of the reporting period were ¥861,463,810.54, a decrease of 5.44% from the end of the previous year[2]. - The company's total assets as of September 30, 2023, amounted to CNY 861,463,810.54, a decrease from CNY 911,018,789.08 at the beginning of the year, reflecting a decline of 5.45%[20]. - The company's total liabilities decreased to CNY 284,606,468.81 from CNY 330,076,360.29, representing a reduction of 13.76%[21]. - The company’s total liabilities decreased by 5.44% compared to the end of the previous year[2]. - Current assets totaled CNY 203,023,149.88 as of September 30, 2023, down 19.53% from CNY 252,394,374.44 at the start of the year[20]. - Non-current assets remained relatively stable at CNY 658,440,660.66, slightly down from CNY 658,624,414.64 at the beginning of the year[20]. - The company's equity attributable to shareholders increased to CNY 525,277,410.41 from CNY 513,547,960.18, showing a growth of 2.68%[21]. Cash Flow - The cash flow from operating activities was -¥27,016,842.34, a decrease of 450.33% year-on-year[2]. - Operating cash flow net amount was negative at ¥27,016,842.34, compared to a negative cash flow of ¥4,909,246.48 in the same period last year[25]. - Investment activities generated a net cash flow of ¥54,456,466.84, a significant improvement from a negative cash flow of ¥60,084,013.11 in the previous year[25]. - Cash and cash equivalents at the end of the period were ¥3,712,099.53, down from ¥21,617,623.48 at the beginning of the period[26]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 43,595[11]. - The largest shareholder, Hainan Shuangcheng Investment Co., Ltd., holds 32.77% of shares, totaling 136,516,546 shares, with 67,500,000 shares pledged[11]. - The second largest shareholder, HSP Investment Holdings Limited, holds 15.51% of shares, totaling 64,599,379 shares, with 16,210,000 shares pledged[11]. - As of September 30, 2023, the number of stock options exercised in the second exercise period is 1,894,090, increasing the total share capital from 414,737,000 shares to 416,631,090 shares[14]. - The company has 75 incentive objects eligible for stock options, with a total of 2,052,750 options available for exercise during the current period[14]. - The company’s independent directors have expressed their opinions on the stock option and restricted stock incentive plan, which has been approved by the board[13]. Investments and Certifications - The company received a GMP certificate from the Saudi Arabian Food and Drug Authority[17]. - The subsidiary Ningbo Shuangcheng passed the FDA CGMP inspection, confirming compliance with US FDA CGMP requirements[17]. - The company invested 20 million RMB in a financial product, with a return of 345,200 RMB received as of December 28, 2022[18]. - The company plans to continue its share reduction plan, which was initially announced in November 2022, but has since been terminated due to funding arrangements[15]. Expenses - Sales expenses decreased to ¥80,597,603.34 from ¥90,994,937.27, a reduction of approximately 11.4% year-over-year[24]. - Research and development expenses were ¥5,967,831.34, down from ¥6,411,937.86, reflecting a decrease of about 6.9%[24]. - The company incurred financial expenses of ¥7,240,785.87, down from ¥8,157,316.28, a decrease of approximately 11.3%[24]. Future Outlook - The company is focusing on new product development and market expansion strategies to enhance future growth prospects[22].